DTE Announces Appointment of Diego Areces as CEO
16.9.2021 08:00:00 EEST | Business Wire | Press release
The Board of DTE ehf. (DTE) (www.dte.ai), a leader in metals intelligence, is pleased to announce the appointment of Diego Areces as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006176/en/
Diego Areces, CEO of DTE (Photo: Business Wire)
Diego Areces, who joined DTE in 2020 after a long tenure at Schneider Electric, succeeds Karl Matthiasson, one of the Company's two founders, who steps into the role of Chief Financial Officer.
The changes reflect DTE's increased commercial focus and reorganization to accelerate its market expansion, as it continues to innovate around its unique elemental analysis LP-LIBS™ technology, advances its real-time and predictive metals intelligence platform to the next level, and launches its forthcoming Series B financing round. Diego Areces' mission will be to lead DTE through its growth phase, while Karl Matthiasson, in his new role as CFO, will focus on solidifying DTE's financial foundation, expanding its global presence and leading the next funding round.
“I'm very pleased to take on the CEO role to continue building on the success of DTE’s technological accomplishments,” commented Mr. Areces. “Our disruptive technology is poised to transform the metals market and the team has developed solid relationships with strategic customers, which collectively form the launch pad of DTE's market expansion. Our metals intelligence platform enabled by our unique elemental analysis technology allows us to deliver beneficial financial and environmental business outcomes to our customers. We see ourselves as significant contributors to a carbon-neutral future and digital transformation towards Industry 4.0 for the industries we serve. I want to thank both Karl and Sveinn, the co-founders and prior CEOs, for their achievements and the support that they have provided to my appointment.”
“We’re delighted to announce Diego’s leadership and are convinced that he is the right person to drive DTE going forward,” commented DTE co-founder and CEO Karl Matthiasson. “We look forward to the next phase of the Company’s evolution and will continue to build a larger, stronger team to deliver the value that we can achieve through unlocking the future of metals.”
Richard MacKellar, Managing Partner at Chrysalix Ventures and Chairman of the Board of DTE, commented, “Chrysalix is excited and supportive of the nomination of Diego Areces as DTE's CEO. We welcome Diego to this new role in the Company as we continue to drive DTE's growth to fulfill its potential in leading a market of new and better, greener, safer, more efficient metals through technological innovation and value-added solutions. I would also like to thank and acknowledge Karl for his outstanding leadership up to this point, which continues with the challenge of leading DTE's financing and next funding rounds.”
Find out more about DTE's metals intelligence solutions at www.dte.ai.
About DTE ehf.
DTE, Unlocking the Future of Metals™, is the leading innovator in real-time intelligence from liquid metals, serving customers across the metals production and manufacturing value chain through maximizing value, sustainability, safety, and efficiency for all stakeholders.
Our purpose is advancing human progress with greener, safer, more efficient, and more valuable metals, contributing to the 1.5-degree challenge while driving its digital transformation towards Industry 4.0 with the next generation of IIoT analysis technology. DTE provides tangible financial and environmental business outcomes from the plant floor to the business levels through valuable intelligence and predictive insights from liquid metals.
IREAS, DTE's unique, connected, real-time intelligence from liquid metals solution seamless integrated IT and OT, combining chemical composition analysis from molten metals based on Liquid-Phase Laser-Induced Breakdown Spectroscopy (LP-LIBS™) with an artificial intelligence-based analytics platform and digital metals intelligence services.
For more information, please visit www.dte.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006176/en/
Contact information
DTE ehf.
Diego Areces, CEO
diego.areces@dte.ai
(+354) 698 0173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom